Q1 2025 Viking Therapeutics Inc Earnings Call Transcript
Key Points
- Viking Therapeutics Inc (VKTX) announced positive data from four separate clinical programs, including VK2735 for obesity and VK2809 for NASH and fibrosis.
- The company made significant progress toward initiating Phase 3 trials for the subcutaneous VK2735 program, expected to commence later this quarter.
- Viking Therapeutics Inc (VKTX) completed enrollment for the Phase 2 trial of the VK2735 oral tablet for obesity, indicating strong interest in the program.
- A long-term manufacturing agreement was secured to support the future commercialization of VK2735, suggesting readiness for large-scale production.
- The company maintains a strong financial position with over $850 million in cash, providing a solid runway for ongoing and future clinical trials.
- Research and development expenses increased significantly to $41.4 million, impacting the company's financials.
- The net loss for the first quarter of 2025 was $45.6 million, a substantial increase from the previous year.
- General and administrative expenses rose to $14.1 million, driven by legal, patent services, and stock-based compensation costs.
- There is uncertainty regarding the potential impact of tariffs on future operations, which could affect commercial activities.
- The company faces logistical challenges in preparing for the Phase 3 trials, including supply chain and site readiness.
Welcome to the Viking Therapeutics' first-quarter 2025 financial results conference call. (Operator Instructions)
As a reminder, this conference call is being recorded today, April 23, 2025. I would now like to turn the conference over to Viking's Manager of Investor Relations, Stephanie Diaz. Please go ahead, Stephanie.
Hello, and thank you for participating in today's call. Joining me today is Brian Lian, Viking's President and CEO; and Greg Zante, Viking's CFO.
Before we begin, I'd like to caution that comments made during this conference call today, April 23, 2025, will contain forward-looking statements under the Safe Harbor provisions of the U.S. Securities Litigation Reform Act of 1995, including statements about Viking's expectations regarding its development activities, timelines and milestones.
Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely reported results should not
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
